MP Materials (MP) J.P. Morgan Natural Resources Conference 2026 summary

Business model evolution and strategic initiatives

• Transitioning to a fully vertically integrated magnet business, with commercial deliveries to foundational customers expected in 2026.

• Independence facility in Texas to expand magnet capacity from 1,000 to 3,000 tons, with a new 10,000-ton 10X facility underway via a public-private partnership.

• Partnership with the Department of War provides a floor price and contracted cash flows, supporting investment confidence and technology advancement.

• Apple and General Motors secured as foundational customers for magnets and recycling, with recycling operations co-located at Mountain Pass.

• Focus on building a robust, ex-China supply chain, emphasizing the strategic value of domestic rare earth production.

Market dynamics and competitive landscape

• Recent Chinese export restrictions highlight the importance of a decoupled Western supply chain, with no immediate business impact expected.

• Demand for rare earth magnets is growing rapidly, with multiple U.S. projects announced but true scale and capability remain key differentiators.

• Ex-China magnet capacity is expanding, but NdPr oxide remains the binding constraint for industry growth.

• Significant investment, time, and intellectual property are required to achieve scale comparable to established operators.

• Leading ex-China magnet manufacturer status targeted, with ongoing technology investments to maintain a competitive edge.

Policy, government support, and financial structure

• Bipartisan legislative efforts are underway to provide tax credits for domestic magnet and electric motor production.

• Public-private partnership with the Department of War ensures minimum EBITDA for the 10X facility and a price floor for NdPr oxide.

• Floor price arrangement has led to a bifurcation in global NdPr pricing, supporting Western producers.

• Structure allows for significant upside as commercial contracts are syndicated, with minimum EBITDA of $140 million and potential to reach $400 million.

• Robust balance sheet and government support enable patient, strategic growth without immediate need for external contracts.